Biological
GSK2202083A clinical trials
- studies test it
- 4
- open now
- 0
- in phase 3
- 0
- first study started
- 2009
How studies write it
Studies that test it under each name
Name
Studies by the year they started
4 studies that test it; most in 2009 (2)
| Year | Studies |
|---|---|
| 2009 | 2 |
| 2010 | 2 |
By phase
A phase 1/2 study counts in both.
- Phase 2
- 4
What it is tested for
Each study’s main condition, where its own words name it.
Who runs them
Industry 4 · Other 0
Often tested with
Tested in the same studies.
PHiD-CV vaccine (1) · 10-valent pneumococcal vaccine (1)
Studies
Open first, then newest update. How each study uses GSK2202083A is read from its arms, and is right about nine times in ten.
Testing it · 4
- Immunogenicity and Safety Study of GlaxoSmithKline Biologicals' GSK2202083A Vaccine Administered as a Booster DoseCompletedPhase 2GlaxoSmithKlineNCT01171989Written as GSK2202083A vaccine
- Immunogenicity and Safety Study of GSK Biologicals' GSK2202083A Vaccine in Healthy Infants at 2, 3 and 4 Months of AgeCompletedPhase 2GlaxoSmithKlineNCT00970307Written as GSK2202083A vaccine
- Study of GlaxoSmithKline Biologicals' GSK2202083A Vaccine in Healthy InfantsCompletedPhase 2GlaxoSmithKlineNCT01090453Written as GSK2202083A vaccine
- Feasibility Study of GlaxoSmithKline Biologicals' GSK2202083A Vaccine in Healthy Infants at 3, 5 and 11 Months of Age.TerminatedPhase 2GlaxoSmithKlineNCT00871741Written as GSK2202083A vaccine